Specialty of Internal Medicine
Medical Association of Athens
From May 2021: Consultant, 1st Department of Internal Medicine “Hygeia”
2017-2021: Consultant, 4th Department of Internal Medicine “Henry Dunant Hospital Center”
2014-2017: Consultant, Internal Medicine Department, Iaso General
2013-2014: Consultant, Internal Medicine Department, “Mitera”, Hygeia Group.
2011-2012: Consultant, 2nd Department of Internal Medicine, General Hospital G.Gennimatas, Athens
2010-2011:Consultant, Internal Medicine Department, General Hospital of Nea Ionia “Agia Olga – Konstantinopouleio”-“General Patision Hospital”, Athens
2009-2010:Senior House Officer, 2nd Department of Internal Medicine, General Hospital “Sismanogleion”, Athens
2008-2009: Consultant, Internal Medicine Department, General Hospital of Theva,Greece
2002-2007: Resident doctor in Internal Medicine in General Hospital “Evagelismos”, Athens, (2002-2003) and in General University Hospital “Attikon”,Athens (2002-2007).
1999-2001: Rural Medical Service at Fourfoura Medical Office and Health Center of Agia Foteini, Rethymnon Prefecture, Crete, Greece
Educational experience
Medical School, University of Ioannina, Greece.Graduation certificate: 1998
Specialty: 2nd Propaedeutic Department of Internal Medicine, University of Athens, General Hospital “Evagelismos”, 2002 – 2003, and General Hospital “Attikon”, 2003 – 2007.
Title of Specialty :2007
Post graduation education:
Clinical Interest
Overal the broad spectrum of Internal Medicine, with special interest on:
Personalized approach of complicated medical cases
Infectious diseases
Diabetes mellitus
Hyperlipidemia
Arterial hypertension
Research Interest:
Infectious diseases,
Diabetes Mellitus
1.Tygecycline for the treatment of patients with clostridium difficile infections.An update of clinical evidenceKechagias KS, Chorepsima S, Triarides N.A, Falagas ME.Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1053-1058. Epub 2020 Jan 11.
2.Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences.Falagas ME, Athanasaki F, Voulgaris GL, Triarides N.A, Vardakas KZ.Int J Antimicrob Agents. 2019 Jan;53 (1):22-28.Epub 2018 Sep 27.Review.
3.An update on adverse drug reactions related to β-lactam antibiotics.Epub 2018 Sep 27.Vardakas K.Z, Kalimeris GD, Triarides N.A, Falagas ME.Expert Opin Drug Saf. 2018 May;17(5):499-508. Epub 2018 Apr 18. Review
4.Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek Hospitals.Falagas ME et Al, Cefiderocol Study Group.J Antimicrob Chemother. 2017 1;72(6):1704-1708
5.Colistin loading dose: evaluation of the published pharmacokinetic and clinical data.Vardakas KZ, Rellos K, Triarides N.A, Falagas ME. Int J Antimicrob Agents.2016 Nov;48
6.Susceptibility of contemporary isolates to fosfomycin: a systemic review of the literature.Vardakas KZ, Legakis NJ, Triarides N.A, Falagas ME.Int J Antimicrob Agents 2016 Apr;47 (4):269-85.
7.Tetracyclines for multidrug resistant Acinetobacter baumanii infections . Falagas ME, Vardakas KZ, Kapaskelis A, Triarides N.A, Roussos NS.Int J Antimicrob Agents.2015 May; 45(5):455-60.
8.Effectiveness and safety of high dose tigecycline-containing regiments for the treatment of severe bacterial infections.Falagas ME, Vardakas KZ, Tsiveriotis KP,Triarides N.A, Tansarli GS.Int J Antimicrob Agents.2014, Jul;44 (1)1-7
9.D-dimers evaluation in hospitalized patients. Haritos D, Triarides N et Al.Medimont International proceedings.Reprinted from 19th International Congress of Thrombosis, Tel Aviv, 2006.
10.Contineous glucose measurement by Glucoday.Comparison with the reference method with Hexokinase.Dimitriades G, Karamoutzos A, Triarides N.et Al.Diab and Metab, 2003.
Call us on 2106867000 to book an appointment with the medical specialist or the department you are interested in.